Congress moves to cap drug prices nationwide using international benchmarks

What it does

This bill requires the HHS Secretary to set annual 'reference prices' for prescription drugs based on the lowest price charged in 12 wealthy countries (Australia, Canada, UK, etc.). Federal health programs—Medicare, Medicaid, VA, TRICARE, and others—cannot pay more than that reference price. Drug manufacturers must also offer the same price to uninsured and privately insured individuals. Manufacturers who refuse face civil penalties of 5 times the overcharge amount; collected penalties fund NIH drug research.

Why we flagged it

The bill's core mechanism is a price ceiling tied to international benchmarks, enforced through civil penalties and applied across federal and private markets. It is fundamentally a price-control measure, not a subsidy, tax, or deregulation.

What the text implies

• The bill applies reference prices to ALL purchasers (uninsured, privately insured), not just federal programs—this is a de facto price control on the entire U.S. drug market, far broader than the title suggests.
• Manufacturers may respond by reducing R&D investment, delaying new drug launches, or withdrawing from the U.S. market—the bill does not address supply-side consequences.
• The Secretary's discretionary authority under subsection (b)(1)(B) to set prices for drugs unavailable in 3+ reference countries is broad and may invite litigation over 'appropriate price' methodology.
• Penalties are calculated on federal program revenue only, but the price ceiling applies to all sales—manufacturers face asymmetric incentives (penalty on federal sales, price cap on all sales).
• The bill does not define 'retail list price' or address rebates, discounts, and negotiated rates already embedded in federal programs—interaction with existing Medicare negotiation authority (IRA) is unclear.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens—particularly Medicare/Medicaid enrollees, veterans, federal employees, and uninsured individuals—gain direct access to lower drug prices. The bill extends the reference price to all purchasers, not just federal programs, reducing out-of-pocket costs across the board. The enforcement mechanism (5× penalty) creates strong incentive for compliance.

Who stands to gain

• Medicare beneficiaries
• Medicaid enrollees
• Veterans (VA)
• TRICARE beneficiaries
• Federal employees
• Uninsured individuals
• Privately insured individuals
• National Institutes of Health (via penalty transfers)

Named in the bill

HHS Secretary, Drug manufacturers, Medicare, Medicaid, TRICARE, Department of Veterans Affairs, Federal Employees Health Benefits Program, Indian Health Care Improvement Act, National Institutes of Health, Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Sweden, Switzerland

Where it stands

3 cosponsors: 2 Democrats, 1 Independents.

• May 14, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 14, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 4 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $860,000 in lobbying spend. A filing names 6 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Jeff Merkley, the sponsor, reported $507,925 in PAC receipts in the 2026 cycle.

• Grifols Shared Services North America Inc — $840,000 on 2 filings
• Drug Policy Alliance — $20,000 on 2 filings

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.